{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T03:07:15Z","timestamp":1790478435732,"version":"4.1.0"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Study Objectives:<\/jats:title><jats:p>Humans with narcolepsy and orexin\/ataxin-3 transgenic (TG) mice exhibit extensive, but incomplete, degeneration of hypo-cretin (Hcrt) neurons. Partial Hcrt cell loss also occurs in Parkinson disease and other neurologic conditions. Whether Hcrt antagonists such as almorexant (ALM) can exert an effect on the Hcrt that remains after Hcrt neurodegeneration has not yet been determined. The current study was designed to evaluate the hypnotic and cataplexy-inducing efficacy of a Hcrt antagonist in an animal model with low Hcrt tone and compare the ALM efficacy profile in the disease model to that produced in wild-type (WT) control animals.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design:<\/jats:title><jats:p>Counterbalanced crossover study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Setting:<\/jats:title><jats:p>Home cage.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients or Participants:<\/jats:title><jats:p>Nine TG mice and 10 WT mice.<\/jats:p><\/jats:sec><jats:sec><jats:title>Interventions:<\/jats:title><jats:p>ALM (30, 100, 300 mg\/kg), vehicle and positive control injections, dark\/active phase onset.<\/jats:p><\/jats:sec><jats:sec><jats:title>Measurements and Results:<\/jats:title><jats:p>During the 12-h dark period after dosing, ALM exacerbated cataplexy in TG mice and increased nonrapid eye movement sleep with heightened sleep\/wake fragmentation in both genotypes. ALM showed greater hypnotic potency in WT mice than in TG mice. The 100 mg\/kg dose conferred maximal promotion of cataplexy in TG mice and maximal promotion of REM sleep in WT mice. In TG mice, ALM (30 mg\/ kg) paradoxically induced a transient increase in active wakefulness. Core body temperature (Tb) decreased after acute Hcrt receptor blockade, but the reduction in Tb that normally accompanies the wake-to-sleep transition was blunted in TG mice.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions:<\/jats:title><jats:p>These complex dose- and genotype-dependent interactions underscore the importance of effector mechanisms downstream from Hcrt receptors that regulate arousal state. Cataplexy promotion by ALM warrants cautious use of Hcrt antagonists in patient populations with Hcrt neurodegeneration, but may also facilitate the discovery of anticataplectic medications.<\/jats:p><\/jats:sec>","DOI":"10.5665\/sleep.2442","type":"journal-article","created":{"date-parts":[[2013,2,28]],"date-time":"2013-02-28T21:26:00Z","timestamp":1362086760000},"page":"325-336","source":"Crossref","is-referenced-by-count":52,"title":["Almorexant Promotes Sleep and Exacerbates Cataplexy in a Murine Model of Narcolepsy"],"prefix":"10.1093","volume":"36","author":[{"given":"Sarah Wurts","family":"Black","sequence":"first","affiliation":[{"name":"1Biosciences Division, SRI International, Menlo Park, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen R.","family":"Morairty","sequence":"additional","affiliation":[{"name":"1Biosciences Division, SRI International, Menlo Park, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon P.","family":"Fisher","sequence":"additional","affiliation":[{"name":"1Biosciences Division, SRI International, Menlo Park, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsui-Ming","family":"Chen","sequence":"additional","affiliation":[{"name":"1Biosciences Division, SRI International, Menlo Park, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepti R.","family":"Warrier","sequence":"additional","affiliation":[{"name":"1Biosciences Division, SRI International, Menlo Park, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas S.","family":"Kilduff","sequence":"additional","affiliation":[{"name":"1Biosciences Division, SRI International, Menlo Park, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2013,3,1]]},"reference":[{"key":"2023032216171037900_","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.tips.2011.03.007","article-title":"Connectomics of orexin-producing neurons: interface of systems of emotion, energy homeostasis and arousal","volume":"32","author":"Sakurai","year":"2011","journal-title":"Trends Pharmacol Sci"},{"key":"2023032216171037900_","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.smrv.2010.12.003","article-title":"Orexin\/hypocretin plays a role in the response to physiological disequilibrium","volume":"15","author":"Sinton","year":"2011","journal-title":"Sleep Med Rev"},{"key":"2023032216171037900_","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0092-8674(00)81973-X","article-title":"Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation","volume":"98","author":"Chemelli","year":"1999","journal-title":"Cell"},{"key":"2023032216171037900_","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0092-8674(00)81965-0","article-title":"The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene","volume":"98","author":"Lin","year":"1999","journal-title":"Cell"},{"key":"2023032216171037900_","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(99)05582-8","article-title":"Hypocretin (orexin) deficiency in human narcolepsy","volume":"355","author":"Nishino","year":"2000","journal-title":"Lancet"},{"key":"2023032216171037900_","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/79690","article-title":"A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains","volume":"6","author":"Peyron","year":"2000","journal-title":"Nat Med"},{"key":"2023032216171037900_","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0896-6273(00)00058-1","article-title":"Reduced number of hypo-cretin neurons in human narcolepsy","volume":"27","author":"Thannickal","year":"2000","journal-title":"Neuron"},{"key":"2023032216171037900_","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0896-6273(01)00293-8","article-title":"Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity","volume":"30","author":"Hara","year":"2001","journal-title":"Neuron"},{"key":"2023032216171037900_","doi-asserted-by":"crossref","first-page":"4649","DOI":"10.1073\/pnas.0400590101","article-title":"Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice","volume":"101","author":"Mieda","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023032216171037900_","first-page":"1119","article-title":"Hypocretin receptor expression in canine and murine narcolepsy models and in hypocretin-ligand deficient human narcolepsy","volume":"31","author":"Mishima","year":"2008","journal-title":"Sleep"},{"key":"2023032216171037900_","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S0896-6273(03)00330-1","article-title":"Distinct narcolepsy syndromes in orexin receptor-2 and orexin null mice: molecular genetic dissection of non-REM and REM sleep regulatory processes","volume":"38","author":"Willie","year":"2003","journal-title":"Neuron"},{"key":"2023032216171037900_","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0301-0082(96)00070-6","article-title":"Pharmacological aspects of human and canine narcolepsy","volume":"52","author":"Nishino","year":"1997","journal-title":"Prog Neurobiol"},{"key":"2023032216171037900_","doi-asserted-by":"crossref","first-page":"4469","DOI":"10.1523\/JNEUROSCI.5560-03.2004","article-title":"Expression of a polyglutamine-ataxin-3 transgene in orexin neurons induces narcolepsy-cataplexy in the rat","volume":"24","author":"Beuckmann","year":"2004","journal-title":"J Neurosci"},{"key":"2023032216171037900_","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1093\/sleep\/30.11.1417","article-title":"Running promotes wakefulness and increases cataplexy in orexin knockout mice","volume":"30","author":"Espana","year":"2007","journal-title":"Sleep"},{"key":"2023032216171037900_","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1093\/sleep\/33.10.1295","article-title":"Dopaminergic regulation of sleep and cataplexy in a murine model of narcolepsy","volume":"33","author":"Burgess","year":"2010","journal-title":"Sleep"},{"key":"2023032216171037900_","doi-asserted-by":"crossref","first-page":"e18697","DOI":"10.1371\/journal.pone.0018697","article-title":"Cholinergic modulation of narcoleptic attacks in double orexin receptor knockout mice","volume":"6","author":"Kalogiannis","year":"2011","journal-title":"PLoS One"},{"key":"2023032216171037900_","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.neuroscience.2009.04.007","article-title":"Feeding-elicited cataplexy in orexin knockout mice","volume":"161","author":"Clark","year":"2009","journal-title":"Neuroscience"},{"key":"2023032216171037900_","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/nm1544","article-title":"Promotion of sleep by targeting the orexin system in rats, dogs and humans","volume":"13","author":"Brisbare-Roch","year":"2007","journal-title":"Nat Med"},{"key":"2023032216171037900_","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s11910-010-0172-9","article-title":"Hypocretin and its emerging role as a target for treatment of sleep disorders","volume":"11","author":"Cao","year":"2011","journal-title":"Curr Neurol Neurosci Rep"},{"key":"2023032216171037900_","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3109\/01677063.2011.566953","article-title":"Promotion of sleep by suvorexanta novel dual orexin receptor antagonist","volume":"25","author":"Winrow","year":"2011","journal-title":"J Neurogenet"},{"key":"2023032216171037900_","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1002\/ana.21836","article-title":"Loss of hypocretin (orexin) neurons with traumatic brain injury","volume":"66","author":"Baumann","year":"2009","journal-title":"Ann Neurol"},{"key":"2023032216171037900_","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1093\/brain\/awm090","article-title":"Hypocretin (orexin) loss in Parkinson's disease","volume":"130","author":"Fronczek","year":"2007","journal-title":"Brain"},{"key":"2023032216171037900_","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/hmg\/ddi004","article-title":"Orexin loss in Huntington's disease","volume":"14","author":"Petersen","year":"2005","journal-title":"Hum Mol Genet"},{"key":"2023032216171037900_","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1093\/brain\/awm097","article-title":"Hypocretin (orexin) cell loss in Parkinson's disease","volume":"130","author":"Thannickal","year":"2007","journal-title":"Brain"},{"key":"2023032216171037900_","unstructured":"Koberstein R \u00a0FischliW \u00a0ClozelM \u00a0AissaouiH \u00a0WellerT Substituted 1,2,3,4-tetrahydroisoquinoline derivatives World Patent:WO2005118548 2005"},{"key":"2023032216171037900_","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1126\/science.1180962","article-title":"Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle","volume":"326","author":"Kang","year":"2009","journal-title":"Science"},{"key":"2023032216171037900_","doi-asserted-by":"crossref","first-page":"e39131","DOI":"10.1371\/journal.pone.0039131","article-title":"Dual hypocretin receptor antagonism is more effective for sleep promotion than antagonism of either receptor alone","volume":"7","author":"Morairty","year":"2012","journal-title":"PLoS One"},{"key":"2023032216171037900_","doi-asserted-by":"crossref","first-page":"111","DOI":"10.5665\/sleep\/32.1.111","article-title":"A consensus definition of cataplexy in mouse models of narcolepsy","volume":"32","author":"Scammell","year":"2009","journal-title":"Sleep"},{"key":"2023032216171037900_","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1523\/JNEUROSCI.13-03-01057.1993","article-title":"Heterozygosity at the canarc-1 locus can confer susceptibility for narcolepsy: induction of cataplexy in heterozygous asymptomatic dogs after administration of a combination of drugs acting on monoaminergic and cholinergic systems","volume":"13","author":"Mignot","year":"1993","journal-title":"J Neurosci"},{"key":"2023032216171037900_","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0006-8993(96)00541-0","article-title":"Local administration of dopaminergic drugs into the ventral teg-mental area modulates cataplexy in the narcoleptic canine","volume":"733","author":"Reid","year":"1996","journal-title":"Brain Res"},{"key":"2023032216171037900_","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1006\/nbdi.2001.0389","article-title":"Hypocretin levels in sporadic and familial cases of canine narcolepsy","volume":"8","author":"Ripley","year":"2001","journal-title":"Neurobiol Dis"},{"key":"2023032216171037900_","doi-asserted-by":"crossref","first-page":"13037","DOI":"10.1523\/JNEUROSCI.3380-06.2006","article-title":"Differential target-dependent actions of coex-pressed inhibitory dynorphin and excitatory hypocretin\/orexin neuropep-tides","volume":"26","author":"Li","year":"2006","journal-title":"J Neurosci"},{"key":"2023032216171037900_","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.neuropharm.2009.08.009","article-title":"Monoaminergic neuronal changes in orexin deficient mice","volume":"58","author":"Mori","year":"2010","journal-title":"Neuropharmacology"},{"key":"2023032216171037900_","doi-asserted-by":"crossref","first-page":"e39131","DOI":"10.1371\/journal.pone.0039131","article-title":"Dual hypocretin receptor antagonism is more effective for sleep promotion than antagonism of either receptor alone","volume":"7","author":"Morairty","year":"2012","journal-title":"PLoS One"},{"key":"2023032216171037900_","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/j.1460-9568.2010.07259.x","article-title":"Narcoleptic orexin receptor knockout mice express enhanced cholinergic properties in laterodorsal tegmental neurons","volume":"32","author":"Kalogiannis","year":"2010","journal-title":"Eur J Neurosci"},{"key":"2023032216171037900_","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0304-3940(01)02270-4","article-title":"Decreased brain histamine content in hypocretin\/orexin receptor-2 mutated narcoleptic dogs","volume":"313","author":"Nishino","year":"2001","journal-title":"Neurosci Lett"},{"key":"2023032216171037900_","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.smrv.2010.08.002","article-title":"The neuronal network responsible for paradoxical sleep and its dysfunctions causing narcolepsy and rapid eye movement (REM) behavior disorder","volume":"15","author":"Luppi","year":"2011","journal-title":"Sleep Med Rev"},{"key":"2023032216171037900_","doi-asserted-by":"crossref","first-page":"6518","DOI":"10.1523\/JNEUROSCI.6506-10.2011","article-title":"Differential roles of orexin receptor-1 and -2 in the regulation of non-REM and REM sSLEEP","volume":"31","author":"Mieda","year":"2011","journal-title":"J Neurosci"},{"key":"2023032216171037900_","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.smrv.2010.05.002","article-title":"Autonomic disturbances in narcolepsy","volume":"15","author":"Plazzi","year":"2011","journal-title":"Sleep Med Rev"},{"key":"2023032216171037900_","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1124\/jpet.109.152009","article-title":"Blockade of orexin-1 receptors attenuates orexin-2 receptor antagonism-induced sleep promotion in the rat","volume":"330","author":"Dugovic","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"2023032216171037900_","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/sleep\/6.2.137","article-title":"The 24-hour rhythm of core temperature in narcolepsy","volume":"6","author":"Mosko","year":"1983","journal-title":"Sleep"},{"key":"2023032216171037900_","doi-asserted-by":"crossref","first-page":"R533","DOI":"10.1152\/ajpregu.00887.2005","article-title":"Elevated body temperature during sleep in orexin knockout mice","volume":"291","author":"Mochizuki","year":"2006","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"2023032216171037900_","first-page":"219","article-title":"Central thermoregulatory effects of neuropeptide Y and orexin A in rats","volume":"86","author":"Balasko","year":"1999","journal-title":"Acta Physiol Hung"},{"key":"2023032216171037900_","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0167-0115(01)00348-2","article-title":"Effects of orexins on energy balance and thermoregulation","volume":"104","author":"Szekely","year":"2002","journal-title":"Regul Pept"},{"key":"2023032216171037900_","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1469-7793.1997.177bi.x","article-title":"Effect of midbrain stimulations on thermoregulatory vasomotor responses in rats","volume":"503","author":"Zhang","year":"1997","journal-title":"J Physiol"},{"key":"2023032216171037900_","doi-asserted-by":"crossref","first-page":"15944","DOI":"10.1523\/JNEUROSCI.3909-11.2011","article-title":"An orexinergic projection from perifornical hypothalamus to raphe pallidus increases rat brown adi-pose tissue thermogenesis","volume":"31","author":"Tupone","year":"2011","journal-title":"J Neurosci"},{"key":"2023032216171037900_","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1124\/mol.109.055152","article-title":"Biochemical and electrophysiological characterization of almorexant, a dual orexin 1 receptor (OX1)\/orexin 2 receptor (OX2) antagonist: comparison with selective OX1 and OX2 antagonists","volume":"76","author":"Malherbe","year":"2009","journal-title":"Mol Pharmacol"},{"key":"2023032216171037900_","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.pnpbp.2008.04.008","article-title":"The role of the CB1 receptor in the regulation of sSLEEP","volume":"32","author":"Murillo-Rodriguez","year":"2008","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"2023032216171037900_","doi-asserted-by":"crossref","first-page":"38812","DOI":"10.1074\/jbc.M602494200","article-title":"Orexin-1 receptor-cannabinoid CB1 receptor heterodimerization results in both ligand-dependent and -independent coordinated alterations of receptor localization and function","volume":"281","author":"Ellis","year":"2006","journal-title":"J Biol Chem"}],"container-title":["Sleep"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/sleep\/article-pdf\/36\/3\/325\/49595699\/sleep_36_3_325.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/sleep\/article-pdf\/36\/3\/325\/49595699\/sleep_36_3_325.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T16:37:15Z","timestamp":1715013435000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/sleep\/article\/36\/3\/325\/2656909"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,1]]},"references-count":49,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2013,3,1]]},"published-print":{"date-parts":[[2013,3,1]]}},"URL":"https:\/\/doi.org\/10.5665\/sleep.2442","relation":{},"ISSN":["0161-8105","1550-9109"],"issn-type":[{"value":"0161-8105","type":"print"},{"value":"1550-9109","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2013,3,1]]},"published":{"date-parts":[[2013,3,1]]}}}